TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07024316: A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Parti

Sponsor: Atlas Molecular Pharma · Phase: PHASE1/PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$2,478,090

Rescue Site Savings

+$1,644,750

Unlock Full NCT07024316 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07024316 Rescue Dossier →